• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Bios September 8, 2021

Xiaohe Liu

Research Scientist, Cancer Research Technologies, Discovery Technologies

Xiaohe Liu, M.D., Ph.D., is a research scientist in oncology who studies the detection, isolation, and characterization of circulating rare cells from blood samples, and other liquid biopsies. Utilizing SRI’s innovative Fiberoptic Array Scanning Technology (FAST) circulating tumor cell detection system, Liu and his team have developed a platform capable of image-based screening of 26 million targets per minute. They have successfully applied this liquid biopsy technology platform to tackle problems not only in cancer liquid biopsies, but also HIV reservoir studies and antibody discovery.

For cancer liquid biopsy applications, Liu’s research focuses on harnessing the power of the FAST platform to identify rare circulating tumor cells and other related components such as cancer-associated fibroblasts and large oncosomes from a single tube of blood draw. This offers the leverage of multi-component analysis in liquid biopsy and provides a more thorough analysis for cancer’s early detection, prognosis, and treatment guidance. Liu and his team recently developed a PD-L1 assay for circulating tumor cells (CTCs), that gives expression information to guide cancer immunotherapy.  From the same blood draw, they are also able to obtain data on changes in tumor microenvironment, which supplements the information needed to help with a patient’s treatment. (https://www.universityofcalifornia.edu/news/crowdfunding-fight-against-c…)

In addition to CTCs, another research interest of Liu’s is studying HIV reservoir cells. Until recently, HIV reservoir cells were considered largely invisible, especially in patients on anti-viral therapy, and this prohibited their identification and the ability to treat patients with residual disease. Enabled by FAST, Liu and his team were able to identify HIV reservoir cells even at 1 cell per 10 million sensitivity, and with superior specificity. Utilizing this unique power of FAST in analyzing HIV reservoir cells, Liu and his team are working with collaborators to develop a novel treatment to eliminate latent HIV virus in patients and achieve complete remission of the disease.

Liu is also applying FAST’s unparalleled capacity for high throughput image-based screening to develop unconventional assays for antibody development, chemical screening, and other applications in molecular and cell biology. He is focused on continuously expanding the pioneering projects for the FAST platform.

Liu has more than 20 years of experience in biomedical research.  Prior to joining SRI, Liu was a primary scientist for new rare cell applications and cancer biomarker discovery at the Palo Alto Research Center (PARC). Earlier, he completed his postdoctoral training in the School of Medicine at the University of Pennsylvania.

Liu received his M.D. degree from China and his Ph.D. in immunology from Thomas Jefferson University in Philadelphia, Pennsylvania.

View Dr. Liu’s selected publications on PubMed. (Search results may include other authors with similar names.)

Recent publications

  • In Situ Spectrophotometric Measurement of Dissolved Inorganic Carbon in Seawater

    SEAS-DIC is a new in situ instrument designed to provide calibrated, high-frequency, long-term measurements of DIC in marine and fresh waters. This instrument, the first spectrophotometric system capable of automated in situ DIC measurements, positions DIC to become a key parameter for in situ CO2-system characterizations.

  • SR16388 Impairs Protein Homeostasis and Induces Autophagy in Diverse Human Cancer Cell Lines

    SR16388 is a novel amino steroid that targets estrogen-binding proteins including genomic estrogen receptors.

  • Development of Functional Assays for p97/VCP Inhibition

    We used p97 siRNA and a recently identified small molecule p97 inhibitor, N2,N4-dibenzylquinazoline- 2,4-diamine (DBeQ) as tools to develop functional assays suitable for further evaluating the activity of potential p97 inhibitors.

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}